APO Research
Talk to an analyst

APO RESEARCH · REPORT

Filgrastim and Biosimilars

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Filgrastim and Biosimilars Industry Growth and Trends Forecast to 2032

28 December 2025112 pages

Choose your research edition.

Industry ResearchFilgrastim and Biosimilars Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Filgrastim and Biosimilars Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Filgrastim and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Filgrastim and Biosimilars Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Filgrastim and Biosimilars Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Filgrastim and Biosimilars market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Filgrastim and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Filgrastim and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Filgrastim and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Filgrastim and Biosimilars include Changchun GeneScience Pharmaceutical, CSPC Baike Biopharma, Shanghai Sunway Biotech, Amoytop Biotech, Qilu Pharmaceutical, Kexing Biopharm, Jiangsu Wuzhong Pharmaceutical, North China Pharmaceutical and Hangzhou Jiuyuan Gene Engineering, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Filgrastim and Biosimilars market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Filgrastim and Biosimilars market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Filgrastim and Biosimilars market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Filgrastim and Biosimilars.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Filgrastim and Biosimilars market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Filgrastim and Biosimilars Market by Company

Changchun GeneScience Pharmaceutical

CSPC Baike Biopharma

Shanghai Sunway Biotech

Amoytop Biotech

Qilu Pharmaceutical

Kexing Biopharm

Jiangsu Wuzhong Pharmaceutical

North China Pharmaceutical

Hangzhou Jiuyuan Gene Engineering

Harbin Pharmaceutical Group

Chengdu Institute of Biological Products

SL Pharm

Teva

Tanvex BioPharma

Sandoz

Pfizer

Kashiv BioSciences

Amgen

Filgrastim and Biosimilars Segment by Type

Single-use Vials

Prefilled Syringes

Filgrastim and Biosimilars Segment by Application

Hospital and Clinic

Pharmacy

Other

Filgrastim and Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Filgrastim and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Filgrastim and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Filgrastim and Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Filgrastim and Biosimilars manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Filgrastim and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Single-use Vials Table 2. Major Company of Prefilled Syringes Table 3. Global Filgrastim and Biosimilars Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Filgrastim and Biosimilars Sales by Type (2021-2026) & (K Units) Table 5. Global Filgrastim and Biosimilars Sales Market Share in Volume by Type (2021-2026) Table 6. Global Filgrastim and Biosimilars Sales by Type (2021-2026) & (US$ Million) Table 7. Global Filgrastim and Biosimilars Sales Market Share in Value by Type (2021-2026) Table 8. Global Filgrastim and Biosimilars Price by Type (2021-2026) & (US$/Unit) Table 9. Global Filgrastim and Biosimilars Sales by Type (2027-2032) & (K Units) Table 10. Global Filgrastim and Biosimilars Sales Market Share in Volume by Type (2027-2032) Table 11. Global Filgrastim and Biosimilars Sales by Type (2027-2032) & (US$ Million) Table 12. Global Filgrastim and Biosimilars Sales Market Share in Value by Type (2027-2032) Table 13. Global Filgrastim and Biosimilars Price by Type (2027-2032) & (US$/Unit) Table 14. North America Filgrastim and Biosimilars Sales by Type (2021-2026) & (K Units) Table 15. North America Filgrastim and Biosimilars Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Filgrastim and Biosimilars Sales by Type (2021-2026) & (K Units) Table 17. Europe Filgrastim and Biosimilars Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Filgrastim and Biosimilars Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Filgrastim and Biosimilars Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Filgrastim and Biosimilars Sales by Type (2021-2026) & (K Units) Table 21. Latin America Filgrastim and Biosimilars Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Filgrastim and Biosimilars Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Filgrastim and Biosimilars Sales by Type (2021-2026) & (US$ Million) Table 24. Filgrastim and Biosimilars Industry Trends Table 25. Filgrastim and Biosimilars Industry Drivers Table 26. Filgrastim and Biosimilars Industry Opportunities and Challenges Table 27. Filgrastim and Biosimilars Industry Restraints Table 28. Global Filgrastim and Biosimilars Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Filgrastim and Biosimilars Revenue Market Share by Company (2021-2026) Table 30. Global Filgrastim and Biosimilars Sales by Company (2021-2026) & (K Units) Table 31. Global Filgrastim and Biosimilars Sales Share by Company (2021-2026) Table 32. Global Filgrastim and Biosimilars Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Filgrastim and Biosimilars Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Filgrastim and Biosimilars Major Company Production Sites and Headquarters Table 35. Global Filgrastim and Biosimilars Company, Product Type & Application Table 36. Global Filgrastim and Biosimilars Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Filgrastim and Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Filgrastim and Biosimilars Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Filgrastim and Biosimilars Sales by Region (2021-2026) & (K Units) Table 41. Global Filgrastim and Biosimilars Sales Market Share in Volume by Region (2021-2026) Table 42. Global Filgrastim and Biosimilars Sales by Region (2021-2026) & (US$ Million) Table 43. Global Filgrastim and Biosimilars Sales Market Share in Value by Region (2021-2026) Table 44. Global Filgrastim and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Filgrastim and Biosimilars Sales by Region (2027-2032) & (K Units) Table 46. Global Filgrastim and Biosimilars Sales Market Share in Volume by Region (2027-2032) Table 47. Global Filgrastim and Biosimilars Sales by Region (2027-2032) & (US$ Million) Table 48. Global Filgrastim and Biosimilars Sales Market Share in Value by Region (2027-2032) Table 49. Global Filgrastim and Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Filgrastim and Biosimilars Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Filgrastim and Biosimilars Sales by Application (2021-2026) & (K Units) Table 52. Global Filgrastim and Biosimilars Sales Market Share in Volume by Application (2021-2026) Table 53. Global Filgrastim and Biosimilars Sales by Application (2021-2026) & (US$ Million) Table 54. Global Filgrastim and Biosimilars Sales Market Share in Value by Application (2021-2026) Table 55. Global Filgrastim and Biosimilars Price by Application (2021-2026) & (US$/Unit) Table 56. Global Filgrastim and Biosimilars Sales by Application (2027-2032) & (K Units) Table 57. Global Filgrastim and Biosimilars Sales Market Share in Volume by Application (2027-2032) Table 58. Global Filgrastim and Biosimilars Sales by Application (2027-2032) & (US$ Million) Table 59. Global Filgrastim and Biosimilars Sales Market Share in Value by Application (2027-2032) Table 60. Global Filgrastim and Biosimilars Price by Application (2027-2032) & (US$/Unit) Table 61. North America Filgrastim and Biosimilars Sales by Application (2021-2026) & (K Units) Table 62. North America Filgrastim and Biosimilars Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Filgrastim and Biosimilars Sales by Application (2021-2026) & (K Units) Table 64. Europe Filgrastim and Biosimilars Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Filgrastim and Biosimilars Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Filgrastim and Biosimilars Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Filgrastim and Biosimilars Sales by Application (2021-2026) & (K Units) Table 68. Latin America Filgrastim and Biosimilars Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Filgrastim and Biosimilars Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Filgrastim and Biosimilars Sales by Application (2021-2026) & (US$ Million) Table 71. Changchun GeneScience Pharmaceutical Company Information Table 72. Changchun GeneScience Pharmaceutical Business Overview Table 73. Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Product Portfolio Table 75. Changchun GeneScience Pharmaceutical Recent Development Table 76. CSPC Baike Biopharma Company Information Table 77. CSPC Baike Biopharma Business Overview Table 78. CSPC Baike Biopharma Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. CSPC Baike Biopharma Filgrastim and Biosimilars Product Portfolio Table 80. CSPC Baike Biopharma Recent Development Table 81. Shanghai Sunway Biotech Company Information Table 82. Shanghai Sunway Biotech Business Overview Table 83. Shanghai Sunway Biotech Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Shanghai Sunway Biotech Filgrastim and Biosimilars Product Portfolio Table 85. Shanghai Sunway Biotech Recent Development Table 86. Amoytop Biotech Company Information Table 87. Amoytop Biotech Business Overview Table 88. Amoytop Biotech Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Amoytop Biotech Filgrastim and Biosimilars Product Portfolio Table 90. Amoytop Biotech Recent Development Table 91. Qilu Pharmaceutical Company Information Table 92. Qilu Pharmaceutical Business Overview Table 93. Qilu Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Qilu Pharmaceutical Filgrastim and Biosimilars Product Portfolio Table 95. Qilu Pharmaceutical Recent Development Table 96. Kexing Biopharm Company Information Table 97. Kexing Biopharm Business Overview Table 98. Kexing Biopharm Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Kexing Biopharm Filgrastim and Biosimilars Product Portfolio Table 100. Kexing Biopharm Recent Development Table 101. Jiangsu Wuzhong Pharmaceutical Company Information Table 102. Jiangsu Wuzhong Pharmaceutical Business Overview Table 103. Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Product Portfolio Table 105. Jiangsu Wuzhong Pharmaceutical Recent Development Table 106. North China Pharmaceutical Company Information Table 107. North China Pharmaceutical Business Overview Table 108. North China Pharmaceutical Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. North China Pharmaceutical Filgrastim and Biosimilars Product Portfolio Table 110. North China Pharmaceutical Recent Development Table 111. Hangzhou Jiuyuan Gene Engineering Company Information Table 112. Hangzhou Jiuyuan Gene Engineering Business Overview Table 113. Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Product Portfolio Table 115. Hangzhou Jiuyuan Gene Engineering Recent Development Table 116. Harbin Pharmaceutical Group Company Information Table 117. Harbin Pharmaceutical Group Business Overview Table 118. Harbin Pharmaceutical Group Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Harbin Pharmaceutical Group Filgrastim and Biosimilars Product Portfolio Table 120. Harbin Pharmaceutical Group Recent Development Table 121. Chengdu Institute of Biological Products Company Information Table 122. Chengdu Institute of Biological Products Business Overview Table 123. Chengdu Institute of Biological Products Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Chengdu Institute of Biological Products Filgrastim and Biosimilars Product Portfolio Table 125. Chengdu Institute of Biological Products Recent Development Table 126. SL Pharm Company Information Table 127. SL Pharm Business Overview Table 128. SL Pharm Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. SL Pharm Filgrastim and Biosimilars Product Portfolio Table 130. SL Pharm Recent Development Table 131. Teva Company Information Table 132. Teva Business Overview Table 133. Teva Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Teva Filgrastim and Biosimilars Product Portfolio Table 135. Teva Recent Development Table 136. Tanvex BioPharma Company Information Table 137. Tanvex BioPharma Business Overview Table 138. Tanvex BioPharma Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Tanvex BioPharma Filgrastim and Biosimilars Product Portfolio Table 140. Tanvex BioPharma Recent Development Table 141. Sandoz Company Information Table 142. Sandoz Business Overview Table 143. Sandoz Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Sandoz Filgrastim and Biosimilars Product Portfolio Table 145. Sandoz Recent Development Table 146. Pfizer Company Information Table 147. Pfizer Business Overview Table 148. Pfizer Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Pfizer Filgrastim and Biosimilars Product Portfolio Table 150. Pfizer Recent Development Table 151. Kashiv BioSciences Company Information Table 152. Kashiv BioSciences Business Overview Table 153. Kashiv BioSciences Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 154. Kashiv BioSciences Filgrastim and Biosimilars Product Portfolio Table 155. Kashiv BioSciences Recent Development Table 156. Amgen Company Information Table 157. Amgen Business Overview Table 158. Amgen Filgrastim and Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 159. Amgen Filgrastim and Biosimilars Product Portfolio Table 160. Amgen Recent Development Table 161. North America Filgrastim and Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 162. North America Filgrastim and Biosimilars Sales by Country (2021-2026) & (K Units) Table 163. North America Filgrastim and Biosimilars Sales Market Share by Country (2021-2026) Table 164. North America Filgrastim and Biosimilars Sales Forecast by Country (2027-2032) & (K Units) Table 165. North America Filgrastim and Biosimilars Sales Market Share Forecast by Country (2027-2032) Table 166. North America Filgrastim and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. North America Filgrastim and Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 168. North America Filgrastim and Biosimilars Market Share by Country (2021-2026) Table 169. North America Filgrastim and Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. North America Filgrastim and Biosimilars Market Share Forecast by Country (2027-2032) Table 171. Europe Filgrastim and Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 172. Europe Filgrastim and Biosimilars Sales by Country (2021-2026) & (K Units) Table 173. Europe Filgrastim and Biosimilars Sales Market Share by Country (2021-2026) Table 174. Europe Filgrastim and Biosimilars Sales Forecast by Country (2027-2032) & (K Units) Table 175. Europe Filgrastim and Biosimilars Sales Market Share Forecast by Country (2027-2032) Table 176. Europe Filgrastim and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 177. Europe Filgrastim and Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 178. Europe Filgrastim and Biosimilars Market Share by Country (2021-2026) Table 179. Europe Filgrastim and Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 180. Europe Filgrastim and Biosimilars Market Share Forecast by Country (2027-2032) Table 181. Asia-Pacific Filgrastim and Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 182. Asia-Pacific Filgrastim and Biosimilars Sales by Country (2021-2026) & (K Units) Table 183. Asia-Pacific Filgrastim and Biosimilars Sales Market Share by Country (2021-2026) Table 184. Asia-Pacific Filgrastim and Biosimilars Sales Forecast by Country (2027-2032) & (K Units) Table 185. Asia-Pacific Filgrastim and Biosimilars Sales Market Share Forecast by Country (2027-2032) Table 186. Asia-Pacific Filgrastim and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 187. Asia-Pacific Filgrastim and Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 188. Asia-Pacific Filgrastim and Biosimilars Market Share by Country (2021-2026) Table 189. Asia-Pacific Filgrastim and Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 190. Asia-Pacific Filgrastim and Biosimilars Market Share Forecast by Country (2027-2032) Table 191. Latin America Filgrastim and Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 192. Latin America Filgrastim and Biosimilars Sales by Country (2021-2026) & (K Units) Table 193. Latin America Filgrastim and Biosimilars Sales Market Share by Country (2021-2026) Table 194. Latin America Filgrastim and Biosimilars Sales Forecast by Country (2027-2032) & (K Units) Table 195. Latin America Filgrastim and Biosimilars Sales Market Share Forecast by Country (2027-2032) Table 196. Latin America Filgrastim and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 197. Latin America Filgrastim and Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 198. Latin America Filgrastim and Biosimilars Market Share by Country (2021-2026) Table 199. Latin America Filgrastim and Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 200. Latin America Filgrastim and Biosimilars Market Share Forecast by Country (2027-2032) Table 201. Middle East and Africa Filgrastim and Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 202. Middle East and Africa Filgrastim and Biosimilars Sales by Country (2021-2026) & (K Units) Table 203. Middle East and Africa Filgrastim and Biosimilars Sales Market Share by Country (2021-2026) Table 204. Middle East and Africa Filgrastim and Biosimilars Sales Forecast by Country (2027-2032) & (K Units) Table 205. Middle East and Africa Filgrastim and Biosimilars Sales Market Share Forecast by Country (2027-2032) Table 206. Middle East and Africa Filgrastim and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 207. Middle East and Africa Filgrastim and Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 208. Middle East and Africa Filgrastim and Biosimilars Market Share by Country (2021-2026) Table 209. Middle East and Africa Filgrastim and Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 210. Middle East and Africa Filgrastim and Biosimilars Market Share Forecast by Country (2027-2032) Table 211. Key Raw Materials Table 212. Raw Materials Key Suppliers Table 213. Filgrastim and Biosimilars Distributors List Table 214. Filgrastim and Biosimilars Customers List Table 215. Research Programs/Design for This Report Table 216. Authors List of This Report Table 217. Secondary Sources Table 218. Primary Sources List of Figures Figure 1. Filgrastim and Biosimilars Image Figure 2. Global Filgrastim and Biosimilars Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Filgrastim and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 4. Global Filgrastim and Biosimilars Sales (2021-2032) & (K Units) Figure 5. Single-use Vials Image Figure 6. Global Single-use Vials Sales YoY Growth (2021-2032) & (K Units) Figure 7. Prefilled Syringes Image Figure 8. Global Prefilled Syringes Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Filgrastim and Biosimilars Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Filgrastim and Biosimilars Market Share by Type 2025 VS 2032 Figure 11. North America Filgrastim and Biosimilars Sales Market Share in Volume by Type in 2025 Figure 12. North America Filgrastim and Biosimilars Sales Market Share in Value by Type in 2025 Figure 13. Europe Filgrastim and Biosimilars Sales Market Share in Volume by Type in 2025 Figure 14. Europe Filgrastim and Biosimilars Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Filgrastim and Biosimilars Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Filgrastim and Biosimilars Sales Market Share in Value by Type in 2025 Figure 17. Latin America Filgrastim and Biosimilars Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Filgrastim and Biosimilars Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Filgrastim and Biosimilars Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Filgrastim and Biosimilars Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Filgrastim and Biosimilars Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospital and Clinic Image Figure 24. Global Hospital and Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 25. Pharmacy Image Figure 26. Global Pharmacy Sales YoY Growth (2021-2032) & (K Units) Figure 27. Other Image Figure 28. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global Filgrastim and Biosimilars Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Filgrastim and Biosimilars Market Share by Application 2025 VS 2032 Figure 31. North America Filgrastim and Biosimilars Sales Market Share in Volume by Application in 2025 Figure 32. North America Filgrastim and Biosimilars Sales Market Share in Value by Application in 2025 Figure 33. Europe Filgrastim and Biosimilars Sales Market Share in Volume by Application in 2025 Figure 34. Europe Filgrastim and Biosimilars Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Filgrastim and Biosimilars Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Filgrastim and Biosimilars Sales Market Share in Value by Application in 2025 Figure 37. Latin America Filgrastim and Biosimilars Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Filgrastim and Biosimilars Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Filgrastim and Biosimilars Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Filgrastim and Biosimilars Sales Market Share in Value by Application in 2025 Figure 41. North America Filgrastim and Biosimilars Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America Filgrastim and Biosimilars Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Filgrastim and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Filgrastim and Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Filgrastim and Biosimilars Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe Filgrastim and Biosimilars Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Filgrastim and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Filgrastim and Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Filgrastim and Biosimilars Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific Filgrastim and Biosimilars Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Filgrastim and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Filgrastim and Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Filgrastim and Biosimilars Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America Filgrastim and Biosimilars Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Filgrastim and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Filgrastim and Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Filgrastim and Biosimilars Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa Filgrastim and Biosimilars Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Filgrastim and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Filgrastim and Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Filgrastim and Biosimilars Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Filgrastim and Biosimilars Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Single-use Vials
  • Prefilled Syringes
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Changchun GeneScience Pharmaceutical
  • CSPC Baike Biopharma
  • Shanghai Sunway Biotech
  • Amoytop Biotech
  • Qilu Pharmaceutical
  • Kexing Biopharm
  • Jiangsu Wuzhong Pharmaceutical
  • North China Pharmaceutical
  • Hangzhou Jiuyuan Gene Engineering
  • Harbin Pharmaceutical Group
  • Chengdu Institute of Biological Products
  • SL Pharm
  • Teva
  • Tanvex BioPharma
  • Sandoz
  • Pfizer
  • Kashiv BioSciences
  • Amgen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Filgrastim and Biosimilars Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Filgrastim and Biosimilars Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Filgrastim and Biosimilars Market by Type
  6. 1.3.1 Single-use Vials
  7. 1.3.2 Prefilled Syringes
  8. 1.4 Global Filgrastim and Biosimilars Market Size by Type
  9. 1.4.1 Global Filgrastim and Biosimilars Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Filgrastim and Biosimilars Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Filgrastim and Biosimilars Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Filgrastim and Biosimilars Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Filgrastim and Biosimilars Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Filgrastim and Biosimilars Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Filgrastim and Biosimilars Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Filgrastim and Biosimilars Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Filgrastim and Biosimilars Industry Trends
  2. 2.2 Filgrastim and Biosimilars Industry Drivers
  3. 2.3 Filgrastim and Biosimilars Industry Opportunities and Challenges
  4. 2.4 Filgrastim and Biosimilars Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Filgrastim and Biosimilars Revenue (2021-2026)
  2. 3.2 Global Top Players by Filgrastim and Biosimilars Sales (2021-2026)
  3. 3.3 Global Top Players by Filgrastim and Biosimilars Price (2021-2026)
  4. 3.4 Global Filgrastim and Biosimilars Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Filgrastim and Biosimilars Major Company Production Sites & Headquarters
  6. 3.6 Global Filgrastim and Biosimilars Company, Product Type & Application
  7. 3.7 Global Filgrastim and Biosimilars Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Filgrastim and Biosimilars Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Filgrastim and Biosimilars Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Filgrastim and Biosimilars Tier 1, Tier 2, and Tier 3
4 Filgrastim and Biosimilars Regional Status and Outlook
  1. 4.1 Global Filgrastim and Biosimilars Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Filgrastim and Biosimilars Historic Market Size by Region
  3. 4.2.1 Global Filgrastim and Biosimilars Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Filgrastim and Biosimilars Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Filgrastim and Biosimilars Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Filgrastim and Biosimilars Forecasted Market Size by Region
  7. 4.3.1 Global Filgrastim and Biosimilars Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Filgrastim and Biosimilars Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Filgrastim and Biosimilars Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Filgrastim and Biosimilars by Application
  1. 5.1 Filgrastim and Biosimilars Market by Application
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Filgrastim and Biosimilars Market Size by Application
  6. 5.2.1 Global Filgrastim and Biosimilars Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Filgrastim and Biosimilars Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Filgrastim and Biosimilars Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Filgrastim and Biosimilars Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Filgrastim and Biosimilars Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Filgrastim and Biosimilars Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Filgrastim and Biosimilars Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Filgrastim and Biosimilars Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Changchun GeneScience Pharmaceutical
  2. 6.1.1 Changchun GeneScience Pharmaceutical Company Information
  3. 6.1.2 Changchun GeneScience Pharmaceutical Business Overview
  4. 6.1.3 Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Product Portfolio
  6. 6.1.5 Changchun GeneScience Pharmaceutical Recent Developments
  7. 6.2 CSPC Baike Biopharma
  8. 6.2.1 CSPC Baike Biopharma Company Information
  9. 6.2.2 CSPC Baike Biopharma Business Overview
  10. 6.2.3 CSPC Baike Biopharma Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 CSPC Baike Biopharma Filgrastim and Biosimilars Product Portfolio
  12. 6.2.5 CSPC Baike Biopharma Recent Developments
  13. 6.3 Shanghai Sunway Biotech
  14. 6.3.1 Shanghai Sunway Biotech Company Information
  15. 6.3.2 Shanghai Sunway Biotech Business Overview
  16. 6.3.3 Shanghai Sunway Biotech Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Shanghai Sunway Biotech Filgrastim and Biosimilars Product Portfolio
  18. 6.3.5 Shanghai Sunway Biotech Recent Developments
  19. 6.4 Amoytop Biotech
  20. 6.4.1 Amoytop Biotech Company Information
  21. 6.4.2 Amoytop Biotech Business Overview
  22. 6.4.3 Amoytop Biotech Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Amoytop Biotech Filgrastim and Biosimilars Product Portfolio
  24. 6.4.5 Amoytop Biotech Recent Developments
  25. 6.5 Qilu Pharmaceutical
  26. 6.5.1 Qilu Pharmaceutical Company Information
  27. 6.5.2 Qilu Pharmaceutical Business Overview
  28. 6.5.3 Qilu Pharmaceutical Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Qilu Pharmaceutical Filgrastim and Biosimilars Product Portfolio
  30. 6.5.5 Qilu Pharmaceutical Recent Developments
  31. 6.6 Kexing Biopharm
  32. 6.6.1 Kexing Biopharm Company Information
  33. 6.6.2 Kexing Biopharm Business Overview
  34. 6.6.3 Kexing Biopharm Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Kexing Biopharm Filgrastim and Biosimilars Product Portfolio
  36. 6.6.5 Kexing Biopharm Recent Developments
  37. 6.7 Jiangsu Wuzhong Pharmaceutical
  38. 6.7.1 Jiangsu Wuzhong Pharmaceutical Company Information
  39. 6.7.2 Jiangsu Wuzhong Pharmaceutical Business Overview
  40. 6.7.3 Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Product Portfolio
  42. 6.7.5 Jiangsu Wuzhong Pharmaceutical Recent Developments
  43. 6.8 North China Pharmaceutical
  44. 6.8.1 North China Pharmaceutical Company Information
  45. 6.8.2 North China Pharmaceutical Business Overview
  46. 6.8.3 North China Pharmaceutical Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 North China Pharmaceutical Filgrastim and Biosimilars Product Portfolio
  48. 6.8.5 North China Pharmaceutical Recent Developments
  49. 6.9 Hangzhou Jiuyuan Gene Engineering
  50. 6.9.1 Hangzhou Jiuyuan Gene Engineering Company Information
  51. 6.9.2 Hangzhou Jiuyuan Gene Engineering Business Overview
  52. 6.9.3 Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Product Portfolio
  54. 6.9.5 Hangzhou Jiuyuan Gene Engineering Recent Developments
  55. 6.10 Harbin Pharmaceutical Group
  56. 6.10.1 Harbin Pharmaceutical Group Company Information
  57. 6.10.2 Harbin Pharmaceutical Group Business Overview
  58. 6.10.3 Harbin Pharmaceutical Group Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Harbin Pharmaceutical Group Filgrastim and Biosimilars Product Portfolio
  60. 6.10.5 Harbin Pharmaceutical Group Recent Developments
  61. 6.11 Chengdu Institute of Biological Products
  62. 6.11.1 Chengdu Institute of Biological Products Company Information
  63. 6.11.2 Chengdu Institute of Biological Products Business Overview
  64. 6.11.3 Chengdu Institute of Biological Products Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Chengdu Institute of Biological Products Filgrastim and Biosimilars Product Portfolio
  66. 6.11.5 Chengdu Institute of Biological Products Recent Developments
  67. 6.12 SL Pharm
  68. 6.12.1 SL Pharm Company Information
  69. 6.12.2 SL Pharm Business Overview
  70. 6.12.3 SL Pharm Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 SL Pharm Filgrastim and Biosimilars Product Portfolio
  72. 6.12.5 SL Pharm Recent Developments
  73. 6.13 Teva
  74. 6.13.1 Teva Company Information
  75. 6.13.2 Teva Business Overview
  76. 6.13.3 Teva Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Teva Filgrastim and Biosimilars Product Portfolio
  78. 6.13.5 Teva Recent Developments
  79. 6.14 Tanvex BioPharma
  80. 6.14.1 Tanvex BioPharma Company Information
  81. 6.14.2 Tanvex BioPharma Business Overview
  82. 6.14.3 Tanvex BioPharma Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Tanvex BioPharma Filgrastim and Biosimilars Product Portfolio
  84. 6.14.5 Tanvex BioPharma Recent Developments
  85. 6.15 Sandoz
  86. 6.15.1 Sandoz Company Information
  87. 6.15.2 Sandoz Business Overview
  88. 6.15.3 Sandoz Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Sandoz Filgrastim and Biosimilars Product Portfolio
  90. 6.15.5 Sandoz Recent Developments
  91. 6.16 Pfizer
  92. 6.16.1 Pfizer Company Information
  93. 6.16.2 Pfizer Business Overview
  94. 6.16.3 Pfizer Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Pfizer Filgrastim and Biosimilars Product Portfolio
  96. 6.16.5 Pfizer Recent Developments
  97. 6.17 Kashiv BioSciences
  98. 6.17.1 Kashiv BioSciences Company Information
  99. 6.17.2 Kashiv BioSciences Business Overview
  100. 6.17.3 Kashiv BioSciences Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Kashiv BioSciences Filgrastim and Biosimilars Product Portfolio
  102. 6.17.5 Kashiv BioSciences Recent Developments
  103. 6.18 Amgen
  104. 6.18.1 Amgen Company Information
  105. 6.18.2 Amgen Business Overview
  106. 6.18.3 Amgen Filgrastim and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Amgen Filgrastim and Biosimilars Product Portfolio
  108. 6.18.5 Amgen Recent Developments
7 North America by Country
  1. 7.1 North America Filgrastim and Biosimilars Sales by Country
  2. 7.1.1 North America Filgrastim and Biosimilars Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Filgrastim and Biosimilars Sales by Country (2021-2026)
  4. 7.1.3 North America Filgrastim and Biosimilars Sales Forecast by Country (2027-2032)
  5. 7.2 North America Filgrastim and Biosimilars Market Size by Country
  6. 7.2.1 North America Filgrastim and Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Filgrastim and Biosimilars Market Size by Country (2021-2026)
  8. 7.2.3 North America Filgrastim and Biosimilars Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Filgrastim and Biosimilars Sales by Country
  2. 8.1.1 Europe Filgrastim and Biosimilars Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Filgrastim and Biosimilars Sales by Country (2021-2026)
  4. 8.1.3 Europe Filgrastim and Biosimilars Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Filgrastim and Biosimilars Market Size by Country
  6. 8.2.1 Europe Filgrastim and Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Filgrastim and Biosimilars Market Size by Country (2021-2026)
  8. 8.2.3 Europe Filgrastim and Biosimilars Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Filgrastim and Biosimilars Sales by Country
  2. 9.1.1 Asia-Pacific Filgrastim and Biosimilars Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Filgrastim and Biosimilars Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Filgrastim and Biosimilars Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Filgrastim and Biosimilars Market Size by Country
  6. 9.2.1 Asia-Pacific Filgrastim and Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Filgrastim and Biosimilars Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Filgrastim and Biosimilars Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Filgrastim and Biosimilars Sales by Country
  2. 10.1.1 South America Filgrastim and Biosimilars Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Filgrastim and Biosimilars Sales by Country (2021-2026)
  4. 10.1.3 South America Filgrastim and Biosimilars Sales Forecast by Country (2027-2032)
  5. 10.2 South America Filgrastim and Biosimilars Market Size by Country
  6. 10.2.1 South America Filgrastim and Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Filgrastim and Biosimilars Market Size by Country (2021-2026)
  8. 10.2.3 South America Filgrastim and Biosimilars Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Filgrastim and Biosimilars Sales by Country
  2. 11.1.1 Middle East and Africa Filgrastim and Biosimilars Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Filgrastim and Biosimilars Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Filgrastim and Biosimilars Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Filgrastim and Biosimilars Market Size by Country
  6. 11.2.1 Middle East and Africa Filgrastim and Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Filgrastim and Biosimilars Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Filgrastim and Biosimilars Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Filgrastim and Biosimilars Value Chain Analysis
  2. 12.1.1 Filgrastim and Biosimilars Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Filgrastim and Biosimilars Production Mode & Process
  7. 12.2 Filgrastim and Biosimilars Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Filgrastim and Biosimilars Distributors
  10. 12.2.3 Filgrastim and Biosimilars Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst